Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.

Autor: Toader D; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Fessler SP; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Collins SD; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Conlon PR; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Bollu R; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Catcott KC; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Chin CN; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Dirksen A; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Du B; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Duvall JR; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Higgins S; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Kozytska MV; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Bellovoda K; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Faircloth C; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Lee D; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Li F; Pheon Therapeutics, Cambridge MA 02139., Qin L; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Routhier C; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Shaw P; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Stevenson CA; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Wang J; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Wongthida P; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Ter-Ovanesyan E; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Ditty E; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Bradley SP; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Xu L; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Yin M; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Yurkovetskiy AV; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Mosher R; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Damelin M; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts., Lowinger TB; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, Massachusetts.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2023 Sep 05; Vol. 22 (9), pp. 999-1012.

Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.

Autor: Yurkovetskiy AV; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Bodyak ND; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Yin M; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Thomas JD; Mersana Therapeutics, Cambridge, Massachusetts., Clardy SM; Mersana Therapeutics, Cambridge, Massachusetts., Conlon PR; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Stevenson CA; Mersana Therapeutics, Cambridge, Massachusetts., Uttard A; Mersana Therapeutics, Cambridge, Massachusetts., Qin L; Mersana Therapeutics, Cambridge, Massachusetts., Gumerov DR; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Ter-Ovanesyan E; Mersana Therapeutics, Cambridge, Massachusetts., Bu C; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Johnson AJ; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Gurijala VR; Mersana Therapeutics, Cambridge, Massachusetts., McGillicuddy D; Formerly Mersana Therapeutics, Cambridge, Massachusetts., DeVit MJ; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Poling LL; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Protopopova M; Mersana Therapeutics, Cambridge, Massachusetts., Xu L, Zhang Q; Mersana Therapeutics, Cambridge, Massachusetts., Park PU; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Bergstrom DA; Formerly Mersana Therapeutics, Cambridge, Massachusetts., Lowinger TB; Mersana Therapeutics, Cambridge, Massachusetts. tlowinger@mersana.com.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 May; Vol. 20 (5), pp. 885-895. Date of Electronic Publication: 2021 Mar 15.

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy.

Autor: Yurkovetskiy AV; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Yin M; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Bodyak N; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Stevenson CA; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Thomas JD; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Hammond CE; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Qin L; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Zhu B; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Gumerov DR; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Ter-Ovanesyan E; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Uttard A; Mersana Therapeutics, Inc., Cambridge, Massachusetts., Lowinger TB; Mersana Therapeutics, Inc., Cambridge, Massachusetts. tlowinger@mersana.com.

Publikováno v: Cancer research [Cancer Res] 2015 Aug 15; Vol. 75 (16), pp. 3365-72. Date of Electronic Publication: 2015 Jun 25.

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

Autor: Yurkovetskiy AV; Mersana Therapeutics, Inc., 840 Memorial Drive, Cambridge, MA 02139, USA., Fram RJ

Publikováno v: Advanced drug delivery reviews [Adv Drug Deliv Rev] 2009 Nov 12; Vol. 61 (13), pp. 1193-202. Date of Electronic Publication: 2009 Aug 12.